Effects of an Antioxidant Supplement on Blood Vessel Health
- Conditions
- Healthy
- Interventions
- Dietary Supplement: MitoQDietary Supplement: PlaceboDrug: MitoTempo
- Registration Number
- NCT06424756
- Lead Sponsor
- University of Georgia
- Brief Summary
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and the non-Hispanic Black (NHB) population is disproportionately affected. Our research has previously demonstrated that oxidative stress may contribute to reduced vascular function in otherwise healthy NHB adults, potentially predisposing them to the development of hypertension and CVD. This study is designed to examine whether the mitochondria are an important source of oxidative stress-induced vascular dysfunction in healthy NHB adults.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Self-identify as either non-Hispanic Black or non-Hispanic White.
- Men and women 18-75 years old.
- Non-hypertensive (systolic blood pressure [SBP]<130 and diastolic blood pressure [DBP] <85 mmHg).
- Have low density lipoprotein cholesterol <150mg/dl.
- Have HbA1C <6.0%.
- Rash, skin disease, or disorders of pigmentation (e.g., psoriasis, eczema, vitiligo, or other skin inflammatory skin disorders)
- Known skin allergies to latex or adhesives
- Smoking and/or use of nicotine-containing products within the past year
- Use of illegal/recreational drugs
- Generalized kidney disease
- Taking chloramphenicol, cholestyramine, medication for seizures, methotrexate, nitrofurantoin, tetracycline, barbiturates, steroids, phenobarbital/phenytoin, orlistat or pyrimethamine
- Any current medications which could conceivably alter the cardiovascular control or responses
- Diagnosed or suspected metabolic or cardiovascular disease
- Current pregnancy or breastfeeding
- History of skin or other cancers
- Diagnosed or suspected diabetes (HbA1c ≥6.0)
- Anybody with narcolepsy or who has been diagnosed with any condition that impairs body temperature regulation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description MitoQ, then Placebo SNP - Sodium Nitroprusside Participants will be given a single dose of 80mg MitoQ supplement first following an overnight fast. Then they will receive a matched Placebo single dose within a minimum 14 days MitoQ, then Placebo MitoQ Participants will be given a single dose of 80mg MitoQ supplement first following an overnight fast. Then they will receive a matched Placebo single dose within a minimum 14 days MitoQ, then Placebo Placebo Participants will be given a single dose of 80mg MitoQ supplement first following an overnight fast. Then they will receive a matched Placebo single dose within a minimum 14 days MitoQ, then Placebo MitoTempo Participants will be given a single dose of 80mg MitoQ supplement first following an overnight fast. Then they will receive a matched Placebo single dose within a minimum 14 days Placebo, then MitoQ L-NAME Participants will be given a single dose of Placebo (matched to 80mg MitoQ) first following an overnight fast. Then they will receive 80mg MitoQ supplement single dose within a minimum of 14 days Placebo, then MitoQ SNP - Sodium Nitroprusside Participants will be given a single dose of Placebo (matched to 80mg MitoQ) first following an overnight fast. Then they will receive 80mg MitoQ supplement single dose within a minimum of 14 days MitoQ, then Placebo L-NAME Participants will be given a single dose of 80mg MitoQ supplement first following an overnight fast. Then they will receive a matched Placebo single dose within a minimum 14 days Placebo, then MitoQ MitoQ Participants will be given a single dose of Placebo (matched to 80mg MitoQ) first following an overnight fast. Then they will receive 80mg MitoQ supplement single dose within a minimum of 14 days Placebo, then MitoQ Placebo Participants will be given a single dose of Placebo (matched to 80mg MitoQ) first following an overnight fast. Then they will receive 80mg MitoQ supplement single dose within a minimum of 14 days Placebo, then MitoQ MitoTempo Participants will be given a single dose of Placebo (matched to 80mg MitoQ) first following an overnight fast. Then they will receive 80mg MitoQ supplement single dose within a minimum of 14 days Placebo, then MitoQ Tempol Participants will be given a single dose of Placebo (matched to 80mg MitoQ) first following an overnight fast. Then they will receive 80mg MitoQ supplement single dose within a minimum of 14 days MitoQ, then Placebo Tempol Participants will be given a single dose of 80mg MitoQ supplement first following an overnight fast. Then they will receive a matched Placebo single dose within a minimum 14 days
- Primary Outcome Measures
Name Time Method Cutaneous microvascular responses to local heating 1 hour post intervention Using intradermal microdialysis, skin blood vessels will be locally treated with a mitochondria-targeted antioxidant (MitoTempo; 1 mM concentration). Nitric oxide (NO)-mediated skin vasodilation will be quantified via local inhibition of endothelial NO synthase during the course of the local skin heating protocol using L-NAME (15 mM concentration). Finally, maximal skin blood flow will be measured by heating the local area of skin to 43 degrees Celsius and locally perfusing sodium nitroprusside (SNP; an NO donor; 28 mM concentration). Two (2) thin fiber optic laser Doppler flowmeter probes and their holders, containing local heaters, will be used to measure skin blood flow.
Mitochondrial ROS production in peripheral blood mononuclear cells (PBMCs) 1 hour post intervention Blood will be drawn for isolation of PBMCs and measurement of mitochondrial function and oxidative stress production.
Flow-mediated dilation responses 1 hour post intervention FMD measures the health of blood vessels. The ultrasound makes sound waves to measure the size of blood vessels and the speed of the blood during rest and occlusion. The cuff is inflated to 220 mmHg (a commonly-used suprasystolic pressure; i.e., arterial blood flow is completely occluded) for 5 minutes to stop blood flow to and from the forearm.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ramsey Student Center, University of Georgia
🇺🇸Athens, Georgia, United States